...
首页> 外文期刊>Acta gastro-enterologica Belgica >Sorafenib induced hepatic encephalopathy
【24h】

Sorafenib induced hepatic encephalopathy

机译:索拉非尼诱发肝脑病

获取原文
获取原文并翻译 | 示例
           

摘要

A 60 year old male, known case of Hepatitis C related cirrhosis was diagnosed with exophytic Hepatocellular carcinoma (size 2.1 x 2.2 cm), Barcelona Clinic Liver Cancer Stage A, on routine surveillance. He refused liver Transplant and underwent laparoscopic segmental resection. Thereafter patient was started on Tablet Sorafenib 400mg twice daily to prevent recurrence of Hepatocellular carcinoma. On 18st post-operative day, patient presented with Hepatic encephalopathy. Routine investigations and MRI Brain were normal; Venous ammonia was high. Sorafenib was discontinued, and neurological symptoms resolved within 24 hours. The ammonia level decreased from 112 to 30 μmoVL. Hepatic encephalopathy recurred 14 days after Sorafenib reintroduction at a dose of 400 mg / day. It resolved within 24 hours of withdrawal of Sorafenib. Sorafenib induced recurrent acute overt Hepatic encephalopathy with biochemical corroboration is reported here.
机译:一名60岁的男性,已知丙型肝炎病例相关肝硬化被诊断出患有突出的肝细胞癌(大小2.1×2.2厘米),巴塞罗那临床肝癌阶段A,关于常规监测。 他拒绝肝脏移植和接受腹腔镜节段切除术。 此后患者每天两次在片剂Sorafenib 400mg上开始,以防止肝细胞癌复发。 在术后第18天,患者患有肝脑病。 常规调查和MRI大脑正常; 静脉氨很高。 Sorafenib被停产,神经系统症状在24小时内解决。 氨水量从112降至30μmov1。 肝脏脑病在400毫克/天的剂量下重新介绍后14天。 它在索拉非尼撤离后24小时内解决。 据报道,Sorafenib诱导复发性急性明显肝脏患有生化铬化的肝脏脑病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号